Rentokil (RTO) drops as Q1 update flags weaker international growth, hygiene slump
Rentokil Initial ADS (RTO) is sliding as investors continue to digest its April 16 Q1 2026 trading update, where International organic growth lagged expectations and Hygiene & Wellbeing in North America declined. The pullback also comes days after the company issued $500 million of new notes due 2031, adding fresh focus on leverage and funding needs.
1. What’s moving the stock
Rentokil Initial’s U.S.-listed ADSs are lower as the market continues to price in softer-than-expected momentum outside North America and ongoing weakness in its Hygiene & Wellbeing line. In its Q1 2026 trading update (covering Jan. 1 to Mar. 31, 2026), the company reported total organic revenue growth of 3.4%, but International organic growth was 2.8%, while North America Hygiene & Wellbeing posted negative organic growth.
2. Key Q1 figures investors are reacting to
The Q1 statement showed group revenue of $1,677 million (+4.3% constant currency) with North America revenue of $995 million and International revenue of $682 million. Within North America, pest control remained a key support, but Hygiene & Wellbeing was a drag, with organic revenue down 2.7% for the quarter.
3. Balance-sheet overhang adds to pressure
Separate from the operating debate, attention has also turned to the capital structure after a financing transaction disclosed in late April: a wholly owned subsidiary issued $500 million of senior unsecured notes due 2031, guaranteed by the parent. While proceeds and use-of-funds details can vary by issuance, the timing has amplified investor sensitivity to leverage, refinancing costs, and the pace of operational improvement.